TONIX Pharmaceuticals Holding Corp. (TNXP) is “One to Watch”

TONIX Pharmaceuticals, a New York based company developing treatments for challenging disorders of the central nervous system (CNS), has a unique approach to drug research and development. Instead of going through the time and expense of discovering and developing a new drug from scratch, the company uses ongoing advances in science and medicine to search for potential therapeutic solutions among already existing prescription pharmaceutical agents, drugs that have been used successfully for treating other conditions. Once a promising candidate has been determined, TONIX researches and creates new dose formulations for the agents, with the ultimate goal of producing a new product that may be safer and more effective than currently available treatments.

The company’s lead product candidate is TNX-102, a new optimized dosage of cyclobenzaprine, a popular muscle relaxant. TONIX sees TNX-102 as a possible treatment for the management of fibromyalgia syndrome (FM). FM is a condition of the central nervous system characterized by diffuse musculoskeletal pain, including a heightened and painful response to pressure, often together with fatigue and disturbed sleep. Some FM patients suffer from sensitivity to other stimulations, including odors, noise, bright lights, medications, and even certain foods. It is estimated to affect as many as 1 in 50 Americans.

The company’s other leading product candidate is TNX-105, also based upon cyclobenzaprine, to treat the symptoms of post-traumatic stress disorder (PTSD), considered a psychiatric disorder brought on by highly traumatic experiences. PTSD can be triggered by war experiences, crime experiences, severe accidents, or even a serious personal loss such as a death or divorce. PTSD can manifest itself in sleep disorders, hyperarousal to certain stimuli, inability to concentrate, and various other symptoms.

For additional information, visit the company’s website at www.TonixPharma.com


About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html